# reload+after+2024-01-22 12:43:10.293583
address1§1165 Eastlake Avenue East
city§Seattle
state§WA
zip§98109
country§United States
phone§206 659 0067
fax§206 659 0667
website§https://www.adaptivebiotech.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
fullTimeEmployees§790
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Chad M. Robins M.B.A.', 'age': 49, 'title': 'Co-Founder, CEO & Chairman', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1185288, 'exercisedValue': 248744, 'unexercisedValue': 1799872}, {'maxAge': 1, 'name': 'Ms. Julie  Rubinstein', 'age': 51, 'title': 'President & COO', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 760464, 'exercisedValue': 0, 'unexercisedValue': 294420}, {'maxAge': 1, 'name': 'Dr. Harlan S. Robins Ph.D.', 'age': 50, 'title': 'Co-Founder & Chief Scientific Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 759605, 'exercisedValue': 0, 'unexercisedValue': 551517}, {'maxAge': 1, 'name': 'Mr. Tycho W. Peterson', 'age': 50, 'title': 'Chief Financial Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 539730, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kyle  Piskel', 'age': 39, 'title': 'VP & Principal Accounting Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 375905, 'exercisedValue': 0, 'unexercisedValue': 16358}, {'maxAge': 1, 'name': 'Dr. Sharon  Benzeno Ph.D.', 'age': 49, 'title': 'Chief Commercial Officer of Immune Medicine', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 671291, 'exercisedValue': 0, 'unexercisedValue': 89925}, {'maxAge': 1, 'name': 'Mr. Christopher  Carlson Ph.D.', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Yi  Zhou', 'title': 'Chief Technical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Karina  Calzadilla', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stacy L. Taylor', 'age': 63, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§8
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.25
priceToSalesTrailing12Months§3.6900234
currency§USD
dateShortInterest§1702598400
forwardEps§-1.13
pegRatio§-0.16
exchange§NMS
quoteType§EQUITY
shortName§Adaptive Biotechnologies Corpor
longName§Adaptive Biotechnologies Corporation
firstTradeDateEpochUtc§1561642200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§567cfea8-637f-3416-be65-3a350f304bc9
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§6.0
targetMeanPrice§9.17
targetMedianPrice§10.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§4.324
grossMargins§-0.093100004
ebitdaMargins§-0.95402
trailingPegRatio§None
